ClinicalTrials.gg
RecruitingNCT05367245ButyrateUpdated Oct 19, 2026

Ca-Mg Butyrate in Gulf War Illness

A Phase 2 interventional study of Cal-Mag Butyrate and Placebo in Gulf War Illness, Chronic Fatigue and Neurocognitive Dysfunction, sponsored by VA Office of Research and Development. Recruiting at 3 sites in United States. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by VA Office of Research and Development · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.
Updated Oct 19, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
40 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 148 studies in Cognition Disorders with a site in United States — 21 open to participants now, 27 under way, none of them phase 3. Cognition Disorders · United States.

Planned enrollment
47th of 114
120 · median 72
Started
2024
with 6 others
Phase 2
25 of 148
3 open now
Primary completion
2027-12
later than 17 of 26 live
Registered
131st of 148
by date

Among the 148 studies in Cognition Disorders with a site in United States, this one is the 47th largest by planned enrollment of the 114 interventional ones that give a count, is one of 7 that started in 2024, is one of 25 in phase 2, reaches primary completion later than 17 of the 26 other live ones, and was the 131st registered.

Cognition Disorders

399 studies on the registry are indexed under Cognition Disorders; 72 are open to participants now.

Browse Cognition Disorders studies →

Open to participants now

21 of the 148 studies in Cognition Disorders with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 46 Cognition Disorders studies recruiting now, 20 (43%) set no upper age limit and 11 (24%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 40 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 148 studies in Cognition Disorders with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this clinical trial is to determine if treatment with Butyrate formulation that consists of butyric acid as calcium and magnesium derivatives (Ca-Mg Butyrate) improves the physical function of men and women Veterans suffering from Gulf War Illness (GWI). The primary outcome measure is a change from baseline on the Short Form Health Survey 36-item (VSF-36), with respect to physical functioning and symptoms. The secondary outcome will focus on the drug's role in (a) restoring gut microbiome and virome, (b) decreasing gastrointestinal disturbances (constipation, diarrhea, pain), (c) decreasing chronic fatigue, (d) decreasing systemic inflammation, and (e) a decrease in cognitive deficits.

Read the detailed description

Nearly one third of 700,000 military personnel deployed during Desert Shield and Desert Storm (Aug 2, 1990 to July 31, 1991) in the Kuwaiti War Theater are suffering from Gulf War Illness (GWI), an unexplained chronic illness characterized by multiple symptoms. The illness has taken a heavy toll on deployed Veterans' overall quality of life. Recent research has revealed the host gut microbiome's role in gastrointestinal disturbance, systemic inflammation, and neurotrophic abnormalities in Gulf War Illness mouse models. Also, short-chain fatty acids such as butyrate restored a healthy microbiome and improved gut microbial metabolism apart from attenuating GWI symptom persistence in preclinical studies. Butyrate, a nutraceutical endogenously produced in the host gut following bacterial fermentation, has shown promise in gastrointestinal disturbances such as irritable bowel syndrome (IBS) and Inflammatory bowel disease (IBD).

This is a randomized, two-group, double-blind, placebo-controlled, Phase II clinical trial. The treatment group will receive microencapsulated butyrate capsules (600 mg twice a day for 18 weeks). The placebo group will receive a matching placebo formulation twice a day for 18 weeks. However, after two weeks of the treatment (20 weeks) there will be a follow up virtual visits. The primary outcome measure for this clinical trial is a change from baseline of VSF-36 and CVLT III test scores with respect to physical and mental functioning and symptoms. The secondary outcome measures include changes from baseline of host-microbiome signature, intestinal permeability assessment, peripheral pro-inflammatory biomarkers, and GWI-associated symptoms IBS, chronic pain, fatigue, sleep issues, and cognitive impairment.

03

Conditions studied

  • Gulf War Illness
  • Chronic Fatigue
  • Neurocognitive Dysfunction

Browse trials for

Keywords

  • SCFA
  • Gulf War Illness
  • GWI
  • Microbiome
  • Butyric acid
  • Butyrate
04

Who can participate

The criteria were revised on the registry on Oct 19, 2026. See what changed

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Gulf war era veteran deployed 40 and 70 years old, in good health by medical history prior to 1990 meeting GWI case definition of Centers for Disease Control and Prevention (CDC) and Kansas criteria and
  • currently have no exclusionary diagnoses (self- reported) that could reasonably explain the symptoms of their fatiguing illness. The severity of illness is moderate to severe, scoring less than 30 of 100 on the physical domain of VSF36

Exclusion criteria

Exclusion Criteria:

  • Untreated schizophrenia
  • Untreated bipolar disorder
  • Untreated delusional disorders
  • Untreated dementias of any type and
  • active alcoholism or drug abuse
  • Medical conditions excluded include (i) organ failure, (ii) defined rheumatologic inflammatory disorders, and (iii) transplant
  • Use of Butyrate in any form in the 3 months prior to study drug, medications that would impact gut motility, diarrhea, chronic pain, and immune function e.g., , (Last 3 months)
  • drugs or biologic response modifiers within 3 months of study entry will be used as exclusion criteria
  • Pregnancy, or planned pregnancy in the next 6 months
  • more than 35
  • Specific diets that may have enhanced or enriched fiber or butyrogenic formulations (FODMAP)
  • Medications that could potentially impact immune function in the past one month will be excluded (e.g., steroids, antibiotics, immunosuppressives
  • Medications containing supplement calcium or magnesium butyrate should not be taken for at least 3 months before study entry
  • Nutraceuticals that are formulated to impact gut microbiome or immune health) and use of drugs that affect GI motility and use of any antibiotic in the last 2 months
  • Known allergy to butyrate supplements or their derivatives such as sodium salts or hydroxy derivatives of butyrate and/or inactive ingredients of active and placebo soft gelatin will also be excluded
  • Current evidence of celiac disease or late-stage cirrhosis of the liver, Giardia antigen presence, Clostridium difficile toxin in stool, tissue transglutaminase antibody, recent change in gastrointestinal medications, use of drugs that affects gastrointestinal motility, and use of any antibiotic in the last two months also will be excluded
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Cal-Mag-Butyrate

    Take oral capsule as directed (600 mg, twice a day for 18 weeks) with or without food.

    Drug: Cal-Mag Butyrate

  • Placebo comparator
    Placebo for Cal-Mag-Butyrate

    Take oral capsule as directed (600 mg, twice a day for 18 weeks) with or without food.

    Drug: Placebo

Interventions

  • DrugCal-Mag Butyrate

    Supplements

    Also known as: Bodybio Calcium Magnesium Butyrate

  • DrugPlacebo

    Only Cal-Mag but no Butyric acid

    Also known as: Placebo Cal-Mag Butyrate

06

What researchers measure

Primary outcomes

  1. Veterans Short Form 36-Item Health Survey Physical Component Summary

    Veterans Health Survey contains 36 items to measure health functioning from the patient's point of view. Qualify of life will be determined per Short Form-36 for Veterans' quality of life Physical component (PCS) summary scales, range from 0 to 100 with 100 being better; 50 is expected population average.

    Time frame: Change from Baseline at 3, 6, 9, 12, 18 and 20 weeks

Secondary outcomes

  1. California Verbal Learning Test (CVLT-II)

    CVLT-II asks questions about cognitive symptoms related to recall and memory. The CVLT-II is used to measure verbal learning and episodic long-term memory. It assesses learning, short- and long-delayed recall and recognition for a list of 16 shopping items. Subjects are expected to remember a list of words. They are asked to repeat the words remembered 5 times (5 trials). Each of the words correctly remembered, in each trial, is marked as 1 point. The reported data represent the number of correct items for the Trial 1-Trial 5, Short Delay Free Recall, and Long Delay Free Recall. The long-delayed recall is assessed at 20 minutes. The CVLT enables a comprehensive characterization of a participant's memory profile. Scale ranges from 0 to 80 with 80 being the best.

    Time frame: Change from Baseline at 9, 18 and 20 weeks

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jan 2024 (actual). Primary completion is estimated for Dec 2027, 47 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion Oct 2026 → Dec 2027 and completion Mar 2027 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2022
First posted
May 10, 2022
StartActual
Jan 15, 2024
Primary completionEst.
Dec 31, 2027was Oct 2026
CompletionEst.
Dec 31, 2028was Mar 2027
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 10, 2026→Dec 31, 2027
Oct 19, 2026
Study completion
Mar 31, 2027→Dec 31, 2028
Oct 19, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedGulf war era veteran deployed 40 and 70 years old, in good health by medical history prior to 1990 meeting GWI case definition of Centers for Disease Control and Prevention (CDC) and Kansas criteria and
Oct 19, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Miami VA Healthcare System, Miami, FL · Miami, United StatesContact n•••@va.gov · •••7000→n•••@va.gov · •••7000
Oct 19, 2026
Title
Ca-Mg Butyrate in GWIGulf War Illness
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Primary completion Oct 10, 2026→Dec 31, 2027
    Study completion Mar 31, 2027→Dec 31, 2028
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedGulf war era veteran deployed 40 and 70 years old, in good health by medical history prior to 1990 meeting GWI case definition of Centers for Disease Control and Prevention (CDC) and Kansas criteria and
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Miami VA Healthcare System, Miami, FL · Miami, United StatesContact n•••@va.gov · •••7000→n•••@va.gov · •••7000
    Title Ca-Mg Butyrate in GWIGulf War Illness
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05367245
Collaborators
Miami VA Healthcare System, VA Salt Lake City Health Care System
Responsible party
Sponsor
First posted
May 10, 2022
Start date
Jan 15, 2024
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 19, 2026

Study contacts

Saurabh Chatterjee, PhD
Contact
saurabhc@hs.uci.edu
(562) 826-8000
Jonathan Skupsky
Contact
Jonathan.Skupsky@va.gov
(562) 826-8000
Saurabh Chatterjee, PhD
principal investigator · VA Long Beach Healthcare System, Long Beach, CA

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion